Enhertu (trastuzumab deruxtecan) is a monoclonal antibody used to treat adult patients with unresectable or metastatic HER2+Ve breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting, and adult patients with locally advanced or metastatic HER2+Ve gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Dosage: The recommended enhertu dosage for breast cancer is 5.4 mg/kg and for gastric cancer is 6.4 mg/kg administered into the vein through an intravenous (IV) line. Enhertu is administered 1 time every 3 weeks (21-day treatment cycle). A doctor will determine how many treatments you need. Your healthcare provider may slow down or temporarily stop the enhertu infusion if you experience an infusion-related reaction, or permanently stop this medication if you have severe infusion reactions. In case of missed a planned enhertu dose, call your healthcare provider promptly to schedule an appointment. It is not advised to wait until the upcoming planned treatment cycle.
Side Effects: The most commonly reported enhertu side effects include:
- Decreased appetite
Warnings and Precautions:
- Do not administer enhertu 100 mg injection as an intravenous push or bolus. Use of Sodium Chloride Injection must be avoided.
- It is not recommended to substitute enhertu injection for or with trastuzumab or ado-trastuzumab emtansine.
- Monitor patients for complete blood counts prior to starting enhertu 100 mg therapy and prior to each enhertu dose.
- Assess patients for LVEF before starting trastuzumab deruxtecan 100 mg and at regular intervals while on treatment.
- Use of enhertu can be responsible for causing fetal harm when administered to a pregnant woman.